A case is presented of a young, chronic tetraplegic patient who, shortly after achieving therapeutic levels of imipramine, a tricyclic antidepressant (TCA) developed a life-threatening ventricular arrhythmia. Since tetraplegic patients frequently manifest evidence of autonomic supersensitivity, the autonomic effects of the TCA may have led to the cardiac arrhythmia. Caution should be exercised in the use of TCA's in tetraplegic patients.
Introduction
Tricyclic antidepressants (TeA) are the most widely used medication in the treatment of depression. Over the last 15 years, the toxic effects of these drugs have been extensively reported (Preskorn and Irwin, 1982) , and, more recently, the cardiovascular effects of these drugs at therapeutic doses for depression have been documented (Glassman and Bigger, 1981) .
A significant number of chronic tetraplegics are treated for depression with TeAs. Such patients are very sensitive to stimuli that disrupt autonomic homeostasis as a result of blockade of autonomic outflow from the hypothalamus to autonomic end organs (Erickson, 1980) . We present the case of a chronic tetraplegic patient who developed life-threatening ventricular arrhythmias shortly after achieving therapeutic serum levels of TeAs.
Case report
A 25-year-old male tetraplegic patient was admitted to hospital with palpitations.
The patient had suffered a spinal cord injury at age IS years resulting in a complete sensory and motor deficit below C6. Three weeks prior to admission, he was started on imipramine for agitated depression and the dose was slowly increased over a 2-week period to 200 mg PO q hs. On the day of admission, the patient complained of palpitations, nervousness, a 'flushed feeling', dry mouth, urinary retention, confusion, and drowsiness. His imipramine was discontinued and the patient was admitted to hospital. Medications included diazepam 5 mg PO q.i.d. PRN, and dantrolene sodium 50 mg PO t.i.d., both of which he had been taking for many years. The patient denied other drug ingestion, alcohol consumption, fever, chills, change in bowel habits, history of previous palpitations, cardiac disorders including rheumatic heart disease and cardiac murmur or family history for cardiac disease.
Physical examination revealed an anxious and restless white male patient with a pulse of 160/minute and regular, a blood pressure of 140/90, a respiratory rate of 32, and a rectal temperature of 37.S°C. The skin was flushed, warm and dry, without lesions. The head and neck examination was notable only for slightly dilated (5 mm), but normally reactive pupils. The lungs were clear. Examination of the heart revealed a rapid, regular rate; no rubs, murmurs or gallops were heard. The neurological examination was unchanged from previous examina tions, and revealed a sensory and motor level at C6. The patient was unable to void urine, therefore a catheter was placed in the bladder and 500 cc of urine was drained, without change in his vital signs.
Laboratory data revealed a WBC count of 16,700 with a normal differential.
The haemoglobin, haematocrit, glucose, BUN, creatinine, and serum electrolytes were all within normal limits. Cardiac isoenzymes were not detected. A blood and urine toxicology screen was positive only for a therapeutic desipramine (an active breakdown product of imipramine) level of 0.1 mcg/ml. A chest X-ray, an impedance plethysmogram, and an echocardiogram were normal. The EKG revealed sinus tachycardia (rate 150), with a normal QT c interval; a rhythm strip demonstrated occasional unifocal ventricular premature beats. Several urine, blood and sputum cultures showed no significant growth. An arterial blood gas on room air revealed a pH 7.61, pCOz IS, pOz 107. On the second and third hospital days, the desipramine levels were 0.05 mcg/ml and 0.04 mcg/ml, respectively. The dopamine infusion was slowly tapered and then discontinued on the fourth hospital day. The lidocaine was also discontinued on that day without recurrence of any ventricular ectopy. The pulse gradually slowed to 90/min over 4 days. The predischarge EKG was within normal limits. The patient was discharged on the fifteenth hospital day and has remained without further symptoms for 1 year. TeA's are well known to cause ventricular arrhythmias in patients with supratherapeutic levels. There are also scattered reports in the literature of ventricular arrhythmias at therapeutic levels in patients with cardiac disease (Marshall and Faeker, 1982) , but this evidence is controversial (Giardina et at.,
1970)
. Also controversial is the interpretation of plasma TeA levels. While some state that the plasma TeA level correlates well with tissue concentration (Preskorn and Irwin, 1982) , other studies have shown that tissue levels, which are highest in cardiac muscle, can be ten times higher than plasma levels (Hollister, 1978).
The major mechanism postulated for TeA induced ventricular arrhythmias involves the blockade of the re-uptake of norepinephrine at the cell membrane.
This leads to increased levels of norepinephrine and potentiation of neuronal activity which could produce arrhythmias by activating latent pacemaker cells (Thorstrand, 1975) . In tetraplegic patients, sympathetic decentralisation leads to an increase in the responsiveness of cells to norepinephrine due to an increase in the number and/or efficiency of receptors (Mathias, 1976) . In combination with the effect of norepinephrine re-uptake blockade, this heightened sensitivity known to exist in tetraplegic patients could lead to the production of ventricular arrhythmias even at therapeutic levels of TeA.
The case described and the mechanisms proposed suggest that life-threatening complications can occur in tetraplegic patients receiving standard doses of TeA. 
